A record of what Nomura Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Nomura is bullish on Lupin, maintaining a buy rating after the company’s €190 million acquisition of VISUfarma. This acquisition is expected to contribute positively to Lupin's earnings and drive long-term growth, projecting a 16-30% upside.”
Nomura Analysis’s track record (trackable calls only): 89 graded calls · 95% CI 41–62%
Lupin LtdBullishCalled 30 Sep 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Nomura Analysis’s full track record